Recursion Pharmaceuticals (RXRX) Equity Ratio (2020 - 2026)

Recursion Pharmaceuticals has reported Equity Ratio for 7 years, with the latest figure at 0.77 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 6.92% year-over-year to 0.77; the trailing twelve-month figure through Mar 2026 stood at 0.77 (up 6.92% YoY), and the FY2025 full-year result was 0.77, up 7.39% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.77, roughly flat from 0.77 in the prior quarter.
• The five-year high for Equity Ratio was 0.77 in Q4 2025, with the low at 0.63 in Q3 2022.
• Historically, Equity Ratio has averaged 0.71 across 5 years, with a median of 0.71 in 2023.
• The largest YoY upside for Equity Ratio was 178.44% in 2022 against a maximum downside of 30.24% in 2022.
• Recursion Pharmaceuticals' Equity Ratio stood at 0.69 in 2022, then grew by 2.34% to 0.71 in 2023, then rose by 0.76% to 0.71 in 2024, then grew by 7.39% to 0.77 in 2025, then decreased by 0.28% to 0.77 in 2026.
• The last three Equity Ratio figures came in at 0.77 (Q1 2026), 0.77 (Q4 2025), and 0.75 (Q3 2025), per Business Quant data.